Companies › DBV Technologies
1 active drug program in 3 registered trials: 3 Phase 3; Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Viaskin Peanut 250µg (DBV712) Epicutaneous immunotherapy (EPIT) for peanut allergy | – | Phase 3 | Peanut Allergy; Allergy; Allergy, Peanut | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03013517 | Viaskin Peanut 250µg (DBV712) | Phase 3 | Peanut Allergy | Other | Nov 2019 |
| NCT07003919 | Viaskin Peanut 250µg (DBV712) | Phase 3 | Allergy | Other | Nov 2026 |
| NCT05741476 | Viaskin Peanut 250µg (DBV712) | Phase 3 | Allergy, Peanut | Other | Oct 2029 |
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
CUTISS Gameto Merz Aesthetics Merz North America CellTherX
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.